Fabiano Oliveira, M.D., Ph.D.

Associate Scientist, Staff Scientist

Contact: For contact information, search the NIH Enterprise Directory.

Education:

Ph.D., Human Pathology, Federal University of Bahia, Brazil

M.D., Medical School of the Federal University of Bahia, Bahia, Brazil

Languages Spoken: Portuguese, Spanish
Portrait of Fabiano Oliveira, Ph.D., M.D.

Biography

Dr. Fabiano Oliveira earned his M.D., M.Sc., and Ph.D. degrees from the Federal University of Bahia/ Fiocruz. In 2003, he joined the National Institutes of Health (NIH) for a postdoctoral fellowship and was appointed as a staff scientist in 2008. Dr. Oliveira currently serves as an associate scientist/staff scientist at the Laboratory of Malaria and Vector Research, NIAID. Dr. Oliveira's research focuses on mitigating vector-borne diseases by exploiting arthropod vector molecules, particularly salivary proteins that influence host-parasite dynamics. His primary passion lies in international research on infectious diseases in endemic areas, with a strong emphasis on vector-borne diseases. He has collaborated extensively with researchers and institutions in Mali, Brazil, Tunisia, and Cambodia. Presently, Dr. Oliveira works closely with the International Center of Excellence in Research (ICER) in Cambodia on a program aimed at understanding the determinants of dengue outcomes driven by immune responses to insect molecules.

Specific Research Areas

  • Understanding the impact of Aedes aegypti salivary proteins on dengue transmission dynamics and dengue outcomes (Cambodia)
  • Investigating how human immune responses from individuals in endemic areas modulate Aedes aegypti salivary protein functions (Cambodia)
  • Control of early host immune response by arthropod molecules driving the outcome of vector-borne diseases
  • Manipulation of insect microbiota to render arthropods refractory to pathogens (dengue/leishmaniasis)
  • Impact of skin microbiota on the severity of cutaneous leishmaniasis lesions (Mali)
  • Leveraging vector salivary proteins as vaccines/therapeutics against vector-borne diseases